A 2026 meta-analysis examined how well PGT-A biopsies represented the rest of the embryo, and found higher mismatch rates in embryos labeled as aneuploid, especially segmental aneuploid embryos.
Embryo rebiopsy
A 2024 meta-analysis combined the results of 10 studies to show that embryos that are thawed for PGT-A, or rebiopsied after inconclusive results, have lower chances of pregnancy and live birth, with higher miscarriage rates.
Researchers in a 2025 study performed PGT-A on whole embryos, including arrested embryos and different developmental stages, finding high rates of euploidy.
The ASRM has released their 2024 committee opinion on the use of PGT-A, covering the use of PGT-A for patients with a good prognosis, advanced age, donor eggs, recurrent pregnancy loss and more.
Researchers in a 2023 study found increased miscarriage rates with mosaic embryo transfers compared to euploids, with no differences in neonatal outcomes.
Mosaic embryos are able to self-correct and result in a normal baby the majority of the time, without evidence of any chromosomal abnormalities, however there are seven cases (as of 2023, to my knowledge) of a mosaic embryo leading to a birth with the same affected chromosome.
Evidence up to 2022 shows that a single PGT-A biopsy is highly concordant (similar) with the rest of the embryo when the embryo is aneuploid or euploid, but not when it’s mosaic or segmental.
Small studies find that some chaotic embryos can be euploid after PGT-A rebiopsy, while a case report details a live birth after the transfer of a chaotic embryo.
This post covers PGT-A, including how it works, how accurate it is, whether it can damage embryos, how to read PGT-A reports, success rates, mosaic embryos, and why even euploid embryos sometimes fail.